Chronic Lower Back Pain Market Size is Expected to Increase With a CAGR of 3.55% for the Study Period, 2017-2030 in the 7MM
DelveInsight estimates that the current Chronic Lower Back Pain (CLBP) Market is going to rise in the coming decade due to the emergence of novel therapies in the CLBPs market, better diagnosis approaches, and increment in R&D funding
Of the emerging therapies, Braeburn Pharmaceuticals/Camurus, Pfizer/Eli Lilly and Company, Mesoblast, Egalet Corporation are expected to launch their respective products, during the forecast period.
The current CLBP market size is entirely dominated by on supportive treatment regimens along with the drugs that have been approved to treat comorbidities associated with CLBP, and those that are approved for chronic pain usually.
The current opioid prescription market is expected to decline in the coming years because CLBP patients will switch from currently prescribed opioids to emerging opioid therapies, such as Buprenorphine and Egalet‐002.
Limited Chronic Lower Back Pain treatment options are the major market driving forces in the CLBP market.
Lower back pain is a common ailment, and at everyone at a certain point of time must have felt it. However, if the pain persists for more than 3-months, it is referred to as chronic lower back pain and is the second leading cause of the disability and degraded quality of life worldwide. The origin, as well as the intensity of the pain, may vary from an injury, disease to stress and from mild to severe.
Chronic Lower Back Pain Epidemiology
According to DelveInsight's analysis, the total CLBP prevalent population in the 7MM was observed to be 73,802,461 in 2017, which is expected to increase during the study period, i.e., 2017–2030. A higher percentage of diagnosed prevalence was observed for females in comparison to males, in all the 7MM countries, except Japan, wherein males occupy a larger patient pool than females. Also it has been observed that CLBP is mostly diagnosed in the age group of 40–69.
The report offers disease epidemiology in the 7MM for the study period 2017 to 2030 segmented by:
Total Prevalent Population of Chronic Lower Back Pain
Total Diagnosed Prevalent Population of Chronic Lower Back Pain
Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain
Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain
Severity Specific Diagnosed Prevalence of Chronic Lower Back Pain
Number of CLBP Patients on Prescription Medications by different Class
Number of CLBP Patients on Opioids by low dose, high dose and Overdose scenario
Present therapies in the CLBP market only provide temporary relief from the pain. At present the Chronic Lower Back Pain market is dominated by opioids. However, the long-term opioid use results in addiction, hence the current scenario demands products with better safety profile and improved Quality of Life (QoL).
The report offers an exhaustive coverage of the marketed as well as the emerging drugs.
Cymbalta: Eli Lilly and Company
Xtampa: Collegium Pharmaceutical
Butrans: Purdue Pharma
Belbuca: BioDelivery Sciences International And many others
Option for customizing and personalizing research reports as per needs
DelveInsight's Chronic Lower Back Pain (CLBP) Market Insights, Epidemiology and Market Forecast–2030' report proffers an in-depth understanding of Chronic Lower Back Pain, its etiology, and manifestations, a detailed analysis of the disease historical as well as forecasted epidemiology trends, its prevalence, incidence and patient pool. The report covers the comprehensive layout of the available marketed or approved therapies for CLBP and the upcoming therapies in the pipeline in the Chronic Lower Back Pain market with unmet needs, market drivers and barriers that may impact the growth of the market size in the next decade in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Moreover, the Chronic Lower Back Pain Market Insights report lays in front the therapy that has the potential to occupy the significant chunk of the CLBP market, competitors' analysis, key collaborations, licensing opportunities, R&D scenario and significant non-profit organizations working for CLBP patients' relief.
Table of Contents
Chronic Lower Back Pain (CLBP) Market Overview at a Glance
Chronic Lower Back Pain -Disease Background and Overview
Chronic Lower Back Pain Epidemiology Methodology
Chronic Lower Back Pain Epidemiology and Patient Population
United States-specificChronic Lower Back Pain Epidemiology
Japan-specific Chronic Lower Back Pain Epidemiology
Chronic Lower Back Pain Treatment Algorithm, Current Treatment, and Medical Practices
Proposed Guidelines for Chronic Lower Back Pain
Unmet Needs in Chronic Lower Back Pain Market
Chronic Lower Back Pain Marketed Products
Chronic Lower Back Pain Emerging Therapies
Chronic Lower Back Pain Market Forecast Methodology
Chronic Lower Back Pain - 7MM Market Analysis
United States: Chronic Lower Back Pain Market Outlook
EU-5 countries: Chronic Lower Back Pain Market Outlook
DelveInsight's 'Chronic Lower Back Pain - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Chronic Lower Back Pain epidemiology in the 7MM.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. Get a hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.